Download PDF
Thromb Haemost 1990; 64(04): 594-599
DOI: 10.1055/s-0038-1647364
Original Article
Schattauer GmbH Stuttgart

Hypersensitivity to Thromboxane A2 in Cholesterol-Rich Human Platelets

Takuya Tomizuka
The 2nd Department of Internal Medicine, School of Medicine, Chiba University, Chiba, Japan
,
Kyohei Yamamoto
The 2nd Department of Internal Medicine, School of Medicine, Chiba University, Chiba, Japan
,
Aizan Hirai
The 2nd Department of Internal Medicine, School of Medicine, Chiba University, Chiba, Japan
,
Yasushi Tamura
The 2nd Department of Internal Medicine, School of Medicine, Chiba University, Chiba, Japan
,
Sho Yoshida
The 2nd Department of Internal Medicine, School of Medicine, Chiba University, Chiba, Japan
› Author Affiliations
Further Information

Publication History

Received 12 February 1990

Accepted after revision23 July 1990

Publication Date:
25 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The effect of changes in platelet membrane cholesterol content on thromboxane A2 (TXA2)-induced platelet activation was studied. Concentrations of 9,ll-epithio-ll,12-methano-TXA2 (STA2), a stable analogue of TXA2 which can cause half-maximal aggregation and release of [14C]serotonin in cholesterol-rich platelets were significantly lower than those in cholesterol-normal platelets. STA2-induced increase in cytosolic calcium concentration and [32P]phosphatidic acid formation in cholesterol-rich platelets were significantly greater than those in cholesterol-normal platelets. The maximal concentration of binding site (Bmax) for SQ29548 was significantly increased in cholesterol-rich platelets compared with cholesterol-normal platelets, while the equilibrium dissociation rate constant (Kd) for SQ29548 did not differ between cholesterol-rich and cholesterol-normal platelets. The present study suggested that sensitivity to TXA2 was increased by the incorporation of cholesterol into platelet membrane and that the cause of hypersensitivity to TXA2 in cholesterol-rich platelets may be partly explained by an increase in binding capacity for TXA2.

 

  • References

  • 1 Ross R, Glomset J, Kariya B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA 1974; 71: 1207-1210
    CrossrefPubMedGoogle Scholar
  • 2 Ross R, Glomset J. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 368-377
    PubMedGoogle Scholar
  • 3 Weksler BB, Nachman RL. Platelets and atherosclerosis. A J Med 1981; 71: 331-333
    CrossrefPubMedGoogle Scholar
  • 4 Mustard JD, Packham MA. The role of blood and platelets in atherosclerosis and the complication of atherosclerosis. Thromb Diath Haemorrh 1975; 33: 444-456
    PubMedGoogle Scholar
  • 5 Carvalho AC A, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290: 434-438
    CrossrefPubMedGoogle Scholar
  • 6 Tremoli E, Maderna P, Sirtori M, Sirtori CR. Platelet aggregation and malondialdehyde formation in type Ila hypercholesterolemic patients. Elaemostasis 1979; 8: 47-53
    PubMedGoogle Scholar
  • 7 Shattil SJ, Anaya-Galindo R, Bennett J, Colman RW, Cooper RA. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 1975; 55: 636-643
    CrossrefPubMedGoogle Scholar
  • 8 Stuart MJ, Gerrard JM, White JG. Effect of cholesterol on production of thromboxane B2 by platelets in vitro. N Engl J Med 1980; 302: 6-10
    CrossrefPubMedGoogle Scholar
  • 9 Kramer RM, Jakubowski JA, Vaillancourt R, Deykin D. Effect of membrane cholesterol on phospholipid metabolism in thrombin-stimulated platelets. J Biol Chem 1982; 257: 6844-6849
    PubMedGoogle Scholar
  • 10 Tandon N, Harmon JT, Rodbard D, Jamieson GA. Thrombin receptors define responsiveness of cholesterol-modified platelets. J Biol Chem 1983; 258: 11840-11845
    PubMedGoogle Scholar
  • 11 Shattil SJ, Bennett JS, Colman RW, Cooper RA. rAbnormalities of cholesterol-phospholipid composition in platelets and low-density lipoproteins of human hyperbetalipoproteinemia. J Lab Clin Med 1977; 89: 341-353
    PubMedGoogle Scholar
  • 12 Insel PA, Nirenberg P, Turnbull J, Shattil SJ. Relationship between membrane cholesterol, a-adrenergic receptors, and platelet function. J Am Chem Soc 1978; 17: 5269-5274
    PubMedGoogle Scholar
  • 13 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998
    CrossrefPubMedGoogle Scholar
  • 14 Kaibuchi K, Tsuda T, Kikuchi A, Tanimoto T, Takai Y. Enhancement of collagen-induced phosphoinositide turnover by thromboxane A2 analogue through Ca2+ mobilization in human platelets. FEBS Lett 1985; 192: 104-108
    CrossrefPubMedGoogle Scholar
  • 15 Tremoli E, Maderna P, Colli S, Morazzoni G, Sirtori CR. Increased platelet sensitivity and thromboxane B2 formation in type Ila hyper-lipoproteinemic patients. Eur J Clin Invest 1984; 14: 329-333
    CrossrefPubMedGoogle Scholar
  • 16 Moriyama T, Takamura H, Narita H, Tanaka K, Matsuura T, Kito M. Elevation of cytosolic free Ca2+ is directly evoked by thromboxane A2 in human platelets during activation with collagen. J Biochem 1988; 103: 901-902
    CrossrefPubMedGoogle Scholar
  • 17 Ushikubi F, Okuma M, Kanaji K, Sugiyama T, Ogorochi T, Narumiya S, Uchino H. Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality; defective signal transduction with normal binding activity. Thromb Haemostas 1987; 57: 158-164
    PubMedGoogle Scholar
  • 18 Yamamoto K, Hirai A, Tamura Y, Yoshida S. A combined method for the preparation of washed human platelets using prostacyclin and gel filtration. Thromb Res 1988; 50: 733-738
    CrossrefPubMedGoogle Scholar
  • 19 Takenaga M, Kitagawa H, Hirai A, Tamura Y, Yoshida S. Mechanism of anti-platelet aggregatory action of dilazep. J Pharmacobio-Dyn 1985; 8: 77-83
    CrossrefPubMedGoogle Scholar
  • 20 Takenaga M, Hirai A, Terano T, Tamura Y, Kitagawa H, Yoshida S. Comparison of the in vitro effect of eicosapentaenoic acid (EPA)-derived lipoxygenase metabolites on human platelet function with those of arachidonic acid. Thromb Res 1986; 37: 373-384
    PubMedGoogle Scholar
  • 21 Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450
    PubMedGoogle Scholar
  • 22 Yagihara Y, Bleasdale JE, Hawthorne JN. Effects of acetylcholine on the incorporation of [32P]orthophosphate in vitro into the phospholipids of subsynaptosomal membranes from guinea-pig brain. J Neuro Chem 1973; 21: 173-190
    PubMedGoogle Scholar
  • 23 Shaikh NA, Palmer FB St C. Phosphoinositide kinases in chick brain and sciatic nerve, a developmental study. J Neurochem 1977; 28: 395-402
    CrossrefPubMedGoogle Scholar
  • 24 Narumiya S, Okuma M, Ushikubi F. Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species. Br J Pharmacol 1986; 88: 323-331
    CrossrefPubMedGoogle Scholar
  • 25 Hassall DG, Forrest LA, Bruckdorfer KR, Marenah CB, Turner P, Cortese C, Miller NE, Lewis B. Influence of plasma lipoproteins on platelet aggregation in a normal male population. Arteriosclerosis 1983; 3: 332-338
    CrossrefPubMedGoogle Scholar
  • 26 Chen PS, Toribara TY, Warner H. Microdetermination of phosphorus. Anal Chem 1956; 28: 1756-1758
    CrossrefPubMedGoogle Scholar
  • 27 Tallarida RJ, Murray RB. Manual of Pharmacologic Calculations with Computer Programs. (2nd ed.) Springer-Verlag, New York 1986
    PubMedGoogle Scholar
  • 28 Morinelli TA, Niewiarowski S, Daniel JL, Smith JB. Receptor-mediated effects of a PGH2 analogue (U46619) on human platelets. Am J Physiol 1987; 253: H1035-H1043
    PubMedGoogle Scholar
  • 29 Koutouzov S, Remmal A, Marche P, Meyer P. Hypersensitivity of phospholipase C in platelets of spontaneously hypertensive rats. Hypertension 1987; 10: 497-504
    CrossrefPubMedGoogle Scholar
  • 30 Halushka PV, Kochel PJ, Mais DE. Binding of thromboxane A2/ prostaglandin H2 agonists to human platelets. Br J Pharmacol 1987; 91: 223-227
    CrossrefPubMedGoogle Scholar
  • 31 Mais DE, Burch RM, Saussy JrD L, Kochel PJ, Halushka PV. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets. J Pharmacol Exp Ther 1985; 235: 729-734
    PubMedGoogle Scholar
  • 32 Ogletree ML, Harris DN, Greenberg R, Haslanger MF, Nakane M. Pharmacological actions of SQ29548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 1985; 234: 435-441
    PubMedGoogle Scholar
  • 33 Liel N, Mais DE, Halushka PV. Binding of a thromboxane A2/ prostaglandin H2 agonist [3H]U46619 to washed platelets. Prostaglandins 1987; 33: 789-795
    CrossrefPubMedGoogle Scholar
  • 34 Yamamoto K, Hirai A, Tamura Y, Yoshida S. In vitro and in vivo effect of ginseng saponins, major components of Korean red ginseng on human platelet aggregation and arachidonic acid metabolism. J Med Pharm Soc WAKAN-YAKU 1988; 5: 184-190
    PubMedGoogle Scholar
  • 35 Sato T, Maegawa H, Kometani M, Fujii T. Collagen-induced calcium influx is enhanced in platelets from hypercholesterolemic rabbits. Thromb Res 1985; 40: 59-68
    CrossrefPubMedGoogle Scholar